We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+15.34%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$338M
AUM Growth
+$65.4M
Cap. Flow
+$44.6M
Cap. Flow %
13.18%
Top 10 Hldgs %
27.92%
Holding
106
New
39
Increased
24
Reduced
12
Closed
28

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$8.7M
2
GSK icon
GSK
GSK
+$7.94M
3
CNC icon
Centene
CNC
+$7.26M
4
EXAS
Exact Sciences
EXAS
+$6.94M
5
SHPG
Shire pic
SHPG
+$6.83M

Top Sells

Rank Stock Value
1
ATHN
Athenahealth, Inc.
ATHN
+$9.99M
2
IEV icon
iShares Europe ETF
IEV
+$7.22M
3
NUVA
NuVasive, Inc.
NUVA
+$7.07M
4
HUM icon
Humana
HUM
+$6.83M
5
AET
Aetna Inc
AET
+$4.84M

Sector Composition

Rank Sector Weight
1 Healthcare 73.98%
2 Financials 0%
3 Industrials 0%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
76
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$119K 0.04%
24,100
-112,900
-82% -$1.09M
FOMX
77
CALL
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$94K 0.03%
+18,900
New +$182K
OCGN icon
78
Ocugen
OCGN
$444M
$23K 0.01%
225
– –
ALDX icon
79
Aldeyra Therapeutics
ALDX
$91.1M
– –
-125,000
Closed -$669K
AMRN
80
Amarin Corp
AMRN
$298M
– –
-12,500
Closed -$770K
APYX icon
81
Apyx Medical
APYX
$146M
– –
-123,000
Closed -$442K
BSX icon
82
CALL
Boston Scientific
BSX
$73.1B
– –
-200,000
Closed -$4.33M
EWA icon
83
CALL
iShares MSCI Australia ETF
EWA
$1.47B
– –
-100,000
Closed -$2.02M
GKOS icon
84
Glaukos
GKOS
$10.7B
– –
-109,903
Closed -$3.77M
HUM icon
85
Humana
HUM
$46.3B
– –
-33,500
Closed -$6.83M
IEV icon
86
iShares Europe ETF
IEV
$1.7B
– –
-186,000
Closed -$7.22M
ILMN icon
87
Illumina
ILMN
$29B
– –
-35,980
Closed -$4.48M
INGN icon
88
PUT
Inogen
INGN
$163M
– –
-65,000
Closed -$4.37M
SYK icon
89
PUT
Stryker
SYK
$133B
– –
-50,000
Closed -$5.99M
TMO icon
90
PUT
Thermo Fisher Scientific
TMO
$222B
– –
-30,000
Closed -$4.23M
XRAY icon
91
Dentsply Sirona
XRAY
$2.34B
– –
-47,500
Closed -$2.74M
NXGN
92
CALL
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-145,300
Closed -$1.91M
NXGN
93
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-266,617
Closed -$3.51M
NUVA
94
DELISTED
NuVasive, Inc.
NUVA
– –
-105,000
Closed -$7.07M
CFMS
95
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-16,769
Closed -$3.4M
XENT
96
CALL
DELISTED
Intersect ENT, Inc
XENT
– –
-3,000
Closed -$645K
GWPH
97
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-32,250
Closed -$3.6M
AGN
98
PUT
DELISTED
Allergan plc
AGN
– –
-40,000
Closed -$8.4M
ELGX
99
DELISTED
Endologix Inc
ELGX
– –
-50,000
Closed -$3.31M
ELGX
100
PUT
DELISTED
Endologix Inc
ELGX
– –
-460
Closed -$26K
1 2 3
4
5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q1 2017 Portfolio in Review

As of Q1 2017, Pura Vida Investments held 106 positions worth $338M, up 24% from $273M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Pura Vida Investments deployed $44.6M of net new capital in Q1 2017, opening 39 new positions and adding to 24 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 67,500 shares worth $8.18M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 53% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was AbbVie, an estimated $4.26M trimmed.

  • Pura Vida Investments's largest Q1 2017 buy was Alexion Pharmaceuticals: 67,500 shares worth $8.18M.
  • Pura Vida Investments added most to Allergan plc in Q1 2017, an estimated $5.16M increase.
  • Pura Vida Investments's biggest Q1 2017 reduction was AbbVie, cutting an estimated $4.26M.
  • Pura Vida Investments fully exited Athenahealth, Inc. in Q1 2017, selling an estimated $9.99M.
  • Pura Vida Investments's ten largest holdings make up 28% of its $338M portfolio in Q1 2017.
  • Pura Vida Investments opened 39 new positions and closed 28 in Q1 2017.
  • Pura Vida Investments's portfolio value rose 24% quarter-over-quarter to $338M.

Based on Pura Vida Investments's 13F filing for Q1 2017, filed 15 May 2017.